Lymfom kliniske forsøg i Utah
14 studier for Lymfom søger deltagere på steder i Utah.
Byer i Utah
Officiel studietekst (engelsk)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Huntsman Cancer Institute, Salt Lake City
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07013435A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Primary Children's Hospital, Salt Lake City
RekruttererFase 1/2
12 Months – 21 Years · Alle køn · Opdateret 11. sep. 2026 · NCT04870944Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- START Mountain Region, West Valley City
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06678659A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 1. jun. 2026 · NCT05663502Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. maj 2026 · NCT06132503Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. apr. 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Rekrutterer
Alder 21 og opefter · Alle køn · Opdateret 5. feb. 2026 · NCT07390071A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. nov. 2025 · NCT05643742Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.